NSE filing, NSE: GLAND. Summary written from the filing by ALFA Finder's alert engine.
Gland Pharma Ltd: key numbers
- Share price
- ₹3,043.00
- Market cap
- ₹50,213 Cr
- Revenue (annual)
- ₹6,431 Cr
- Net profit (annual)
- ₹1,027 Cr
- P/E (TTM)
- 44.5×Sector 46.5×
- Promoter holding
- 45.75%-6.02% QoQ
- FII holding
- 10.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gland Pharma Ltd
All →Gland Pharma Business Update
Gland Pharma reports that USFDA concluded an unannounced cGMP inspection at its Dundigal formulation facility with four procedural Form 483 observations. No monetary impact is stated, and corrective actions will be submitted within the stipulated period.
Gland Pharma Board Meeting Date
Gland Pharma Ltd scheduled a board meeting for November 06, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ending September 30, 2026.
Gland Pharma Other Announcement
Gland Pharma Limited has filed the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.
Gland Pharma Annual General Meeting
Gland Pharma issued a postal ballot notice to seek shareholder approval for appointing Mr. Xingli Wang as Non-Executive Director. E-voting runs October 7 to November 5, 2026.
Gland Pharma Acquisition Worth ₹199.5 Cr
Gland Pharma Limited's board approved a USD 21 million investment in its subsidiary, Gland USA, to acquire a 60% stake in Novelstar Pharma Inc. This acquisition facilitates business expansion in the USA.
- Value
- ₹199.5 Cr
- Execution
- By October 31, 2026
Gland Pharma Promoter Selling
Fosun Pharma Industrial Pte. Ltd. sold 98,97,000 shares of Gland Pharma Ltd via open market transactions. This reduced their stake from 51.76% to 45.76%.
- Promoter stake change
- -6.00%
Other management change announcements
All →Sayaji Hotels (Indore) Management Change
Sayaji Hotels (Indore) appointed Azhar Yusuf Dhanani as Additional Non-Executive Non-Independent Director effective October 28, 2026. Shareholder approval is required within three months.
Fabtech Technologies Management Change
FABTECH Technologies appointed Mr. Alan Dias as Vice President - HR, a senior management personnel role, effective October 28, 2026. He brings over 24 years of human resources experience.
Parmax Pharma Management Change
Parmax Pharma's independent director Ami Shah resigned effective October 28, 2026. The exit follows a change in management and control of the company.
Sagarsoft (India) Management Change
Sagarsoft (India) appointed Ms. Arcot Ganeshan Monisha as Company Secretary and Compliance Officer, designated as KMP, effective 28 October 2026. Details are provided per Regulation 30 in the annexure.
Chemfab Alkalis Management Change
Chemfab Alkalis approved unaudited Q2/H1 results, committee re-designations, and appointed V. R. Raguraman as Chief Operating Officer (SMP). The senior management appointment is the filing's main business event.
Aeroflex Industries Management Change
Aeroflex Industries reports Drashti Bhil's change from Deputy CFO to CFO, plus Mustafa Kachwala's tenure completion as CFO effective 27 November 2026. Management reshuffle with no money or business event.